• BerGenBio is focused on therapeutics that target the epithelial-mesenchymal-transition (EMT) in cancer, considered to play a critical role in tumor metastasis.

  • Rigel has licensed to BerGenBio, on an exclusive world-wide basis, Rigel's preclinical candidate, R428 (now referred to as BGB324), an AXL kinase inhibitor now in clinical trials in oncology.

  • BerGenBio has initiated a Phase 2 clinical trial with BGB324 in acute myeloid leukemia (AML) resulting in a $3.3M milestone payment to Rigel.

  • BerGenBio has also initiated Phase 2 trials with BGB324 in advanced non-small cell lung cancer (NSCLC) & triple negative breast cancer (TNBC) in combination with Keytruda® in collaboration with MSD.